Highlights of the important and the interesting from the world of healthcare:
One month to apply for $5 million: Small drug and biomedical research firms will have a one-month window to apply for federal tax credits (or grants) that show “significant potential” to produce new drugs or meet unmet medical needs. Firms with less than 250 employees can apply for the credit, which covers up to 50 percent of qualifying research costs up to $5 million annually, from June 21 to July 21.
What’s the HCPEA? It’s pronounced “Hick-pea,” and it may be the first-ever sector-focused private equity trade group: The Healthcare Private Equity Association. But it’s not a lobbying group, according to its founder, Brian Miller of Chicago’s Linden LLC. Rather, it’s a way for private equity investors in healthcare to keep up on what’s happening in the industry, share notes on financial reform developments and train their associates.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Biotech in Brooklyn: The city of New York is readying a biotech facility that could grow to 500,000 square feet and host about 20 startups built on research at the city’s universities.
More on carried interest: James Kwak of the Baseline Scenario offers a lengthy takedown of VC Gerry Langeler’s argument to preserve the venture capital tax breaks. Langeler’s arguments, Kwak writes, “are so full of holes I wonder if even he believes them.”
Abbott in India: Abbott Laboratories is “charging into India” with the $3.7 billion purchase of generic drugmaker Piramal Healthcare Ltd. The deal is part of Abbott’s drive to establish itself as a leading emerging market pharmaceutical player and reflects the growing global importance of generics as well as the rise of India’s consumer market for drugs.
EMRs cut costs? Electronic medical records adoption in hospitals, during the first three years of implementation, is often associated with higher nurse staffing needs and higher costs, as well as increased complications for some patients, according to a study by Arizona State University researchers.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Photo from flickr user NIOSH
